<?xml version='1.0' encoding='utf-8'?>
<document id="29870591"><sentence text="Amenamevir: Studies of Potential CYP2C8- and CYP2B6-Mediated Pharmacokinetic Interactions With Montelukast and Bupropion in Healthy Volunteers."><entity charOffset="0-10" id="DDI-PubMed.29870591.s1.e0" text="Amenamevir" /><entity charOffset="95-106" id="DDI-PubMed.29870591.s1.e1" text="Montelukast" /><entity charOffset="111-120" id="DDI-PubMed.29870591.s1.e2" text="Bupropion" /><pair ddi="false" e1="DDI-PubMed.29870591.s1.e0" e2="DDI-PubMed.29870591.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29870591.s1.e0" e2="DDI-PubMed.29870591.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29870591.s1.e0" e2="DDI-PubMed.29870591.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29870591.s1.e1" e2="DDI-PubMed.29870591.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29870591.s1.e1" e2="DDI-PubMed.29870591.s1.e2" /></sentence><sentence text="Amenamevir (formerly ASP2151) induces cytochrome P450 (CYP)2B6 and CYP3A4 and inhibits CYP2C8"><entity charOffset="0-10" id="DDI-PubMed.29870591.s2.e0" text="Amenamevir" /></sentence><sentence text="  We conducted 2 studies, 1 using montelukast as a probe to assess CYP2C8 and the other bupropion to assess CYP2B6"><entity charOffset="34-45" id="DDI-PubMed.29870591.s3.e0" text="montelukast" /><entity charOffset="88-97" id="DDI-PubMed.29870591.s3.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.29870591.s3.e0" e2="DDI-PubMed.29870591.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29870591.s3.e0" e2="DDI-PubMed.29870591.s3.e1" /></sentence><sentence text="  The montelukast study examined the effect of amenamevir on the pharmacokinetics of montelukast in 24 healthy men: each subject received montelukast 10 mg alone, followed by montelukast 10 mg with amenamevir 400 mg, or vice versa after a washout period"><entity charOffset="6-17" id="DDI-PubMed.29870591.s4.e0" text="montelukast" /><entity charOffset="47-57" id="DDI-PubMed.29870591.s4.e1" text="amenamevir" /><entity charOffset="85-96" id="DDI-PubMed.29870591.s4.e2" text="montelukast" /><entity charOffset="138-149" id="DDI-PubMed.29870591.s4.e3" text="montelukast" /><entity charOffset="175-186" id="DDI-PubMed.29870591.s4.e4" text="montelukast" /><pair ddi="false" e1="DDI-PubMed.29870591.s4.e0" e2="DDI-PubMed.29870591.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29870591.s4.e0" e2="DDI-PubMed.29870591.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29870591.s4.e0" e2="DDI-PubMed.29870591.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29870591.s4.e0" e2="DDI-PubMed.29870591.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29870591.s4.e0" e2="DDI-PubMed.29870591.s4.e4" /><pair ddi="false" e1="DDI-PubMed.29870591.s4.e1" e2="DDI-PubMed.29870591.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29870591.s4.e1" e2="DDI-PubMed.29870591.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29870591.s4.e1" e2="DDI-PubMed.29870591.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29870591.s4.e1" e2="DDI-PubMed.29870591.s4.e4" /><pair ddi="false" e1="DDI-PubMed.29870591.s4.e2" e2="DDI-PubMed.29870591.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29870591.s4.e2" e2="DDI-PubMed.29870591.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29870591.s4.e2" e2="DDI-PubMed.29870591.s4.e4" /><pair ddi="false" e1="DDI-PubMed.29870591.s4.e3" e2="DDI-PubMed.29870591.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29870591.s4.e3" e2="DDI-PubMed.29870591.s4.e4" /></sentence><sentence text="  In the bupropion study, 24 subjects received a single dose of 150 mg bupropion on days 1, 15, 22, and 29, and repeated once-daily doses of 400 mg amenamevir on days 6-15"><entity charOffset="9-18" id="DDI-PubMed.29870591.s5.e0" text="bupropion" /><entity charOffset="71-80" id="DDI-PubMed.29870591.s5.e1" text="bupropion" /><entity charOffset="148-158" id="DDI-PubMed.29870591.s5.e2" text="amenamevir" /><pair ddi="false" e1="DDI-PubMed.29870591.s5.e0" e2="DDI-PubMed.29870591.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29870591.s5.e0" e2="DDI-PubMed.29870591.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29870591.s5.e0" e2="DDI-PubMed.29870591.s5.e2" /><pair ddi="false" e1="DDI-PubMed.29870591.s5.e1" e2="DDI-PubMed.29870591.s5.e1" /><pair ddi="false" e1="DDI-PubMed.29870591.s5.e1" e2="DDI-PubMed.29870591.s5.e2" /></sentence><sentence text="  Amenamevir increased peak concentration and area under the concentration-time curve of montelukast by about 22% (ratio 121"><entity charOffset="89-100" id="DDI-PubMed.29870591.s6.e0" text="montelukast" /></sentence><sentence text="7%, 90%CI [114" /><sentence text="8, 129" /><sentence text="1]; 121% [116" /><sentence text="2, 128" /><sentence text="4], respectively) with a similar increase in hydroxymontelukast (ratio 121"><entity charOffset="45-63" id="DDI-PubMed.29870591.s11.e0" text="hydroxymontelukast" /></sentence><sentence text="4%, 90%CI [106" /><sentence text="4, 138" /><sentence text="5]; 125" /><sentence text="6 % [111" /><sentence text="3, 141" /><sentence text="7])" /><sentence text="  Amenamevir reduced peak concentration and area under the concentration-time curve of bupropion by 16% (84"><entity charOffset="87-96" id="DDI-PubMed.29870591.s18.e0" text="bupropion" /></sentence><sentence text="29%, 90%CI [78" /><sentence text="00, 91" /><sentence text="10]; 84" /><sentence text="07%, 90%CI [78" /><sentence text="85, 89" /><sentence text="63]), with recovery after 1 week; the pharmacokinetics of the primary metabolite hydroxybupropion was unaffected" /><sentence text="  Thus, amenamevir increased plasma concentrations of montelukast and decreased those of bupropion, but it did not do so enough to require dose adjustment of coadministered substrates of either CYP2C8 or CYP2B6"><entity charOffset="54-65" id="DDI-PubMed.29870591.s25.e0" text="montelukast" /><entity charOffset="89-98" id="DDI-PubMed.29870591.s25.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.29870591.s25.e0" e2="DDI-PubMed.29870591.s25.e0" /><pair ddi="false" e1="DDI-PubMed.29870591.s25.e0" e2="DDI-PubMed.29870591.s25.e1" /></sentence><sentence text="" /></document>